Clinical implications of interleukins-31, 32, and 33 in gastric cancer

Figure 3 Correlation of interleukin-31, interleukin-32, and interleukin-33 expression with age. A-D: Positive (brown) interleukin (IL)-31 expression in gastric cancer tissues from patients aged < 60 (A) vs > 60 (B) years and noncancerous tissues (C) plus quantified data (D); E-H: Positive (brown) IL-32 expression in gastric cancer tissues from patients aged < 60 (E) vs > 60 (F) years and noncancerous tissues (G), and quantified data (H); I-L: Positive (brown) IL33 expression in gastric cancer tissues from patients aged < 60 (I) vs > 60 (J) years and noncancerous tissues (K) plus quantified data (L). IL-32 and IL-33 were all decreased in the group of gastric cancer patients aged less than or equal to 60 years. ^aP < 0.01; ^bP < 0.01; ^cP < 0.0001; ^dP < 0.01; ^eP < 0.0001; ^fP < 0.05; ^gP < 0.05. IL: Interleukin.